Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy for moderate to severe acne vulgaris, consisting of topical adapalene (a third-generation retinoid), topical benzoyl peroxide, and oral lymecycline (a tetracycline-class antibiotic). Adapalene acts as an agonist at retinoic acid receptors, promoting cell turnover and reducing inflammation. Benzoyl peroxide exerts bactericidal effects through free radical generation, targeting *Cutibacterium acnes* and helping keep pores clear. Lymecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, reducing the population of acne-causing bacteria. The combination targets both inflammatory and non-inflammatory lesions with a synergistic effect that improves efficacy over monotherapy or dual therapy. This regimen is recommended as first-line treatment for moderate to severe acne vulgaris[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + benzoyl peroxide + lymecycline.